Growth Metrics

Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2026)

Neuroone Medical Technologies filings provide 8 years of Cash & Equivalents readings, the most recent being $2.8 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 112.38% to $2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 million, a 112.38% increase, with the full-year FY2025 number at $6.6 million, up 350.01% from a year prior.
  • Cash & Equivalents hit $2.8 million in Q1 2026 for Neuroone Medical Technologies, down from $3.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $12.9 million in Q1 2022 to a low of $1.1 million in Q4 2024.
  • Median Cash & Equivalents over the past 5 years was $3.6 million (2025), compared with a mean of $4.7 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 72.57% in 2024 and later surged 396.28% in 2025.
  • Neuroone Medical Technologies' Cash & Equivalents stood at $4.7 million in 2022, then tumbled by 42.56% to $2.7 million in 2023, then plummeted by 57.69% to $1.1 million in 2024, then surged by 217.36% to $3.6 million in 2025, then decreased by 22.11% to $2.8 million in 2026.
  • The last three reported values for Cash & Equivalents were $2.8 million (Q1 2026), $3.6 million (Q4 2025), and $6.6 million (Q3 2025) per Business Quant data.